AVDL - Wutah dodolan YoY (TTM) avadel.com

Tandha merek Avadel Corp (AVDL)

Avadel Pharmaceuticals (AVDL) is developing the psychoneurology market through its convenient drug Lumryz, although patent litigation and slow insurance coverage are hindering expansion. This TTM annual sales growth chart visualizes this trend, where the 79.70 mark reflects the current state of revenue. Supply stability is maintained through logistics diversification and the creation of warehouse reserves to eliminate drug shortages.

AVDL (Avadel Pharmaceuticals plc) riwayat Wutah dodolan YoY (TTM) saka 11.02.2024 nganti 28.02.2026

Avadel Corp (AVDL) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
Analisis kabeh metrik perusahaan:Avadel Pharmaceuticals (AVDL)
Barang unggulan Avadel Pharma

Focusing on the US domestic market, Avadel Pharmaceuticals (AVDL) is exposed to risks of raw material supply chain disruptions from Asia, which directly impacts sales volumes. By analyzing this 12-month rolling YoY revenue growth chart, an investor can observe sales dynamics without quarterly distortions or low-base effects, making it possible to distinguish sustainable business scaling from one-off spikes and avoid overpaying for the asset.